Bio-Techne Announces Changes to its Leadership Team
Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) announced leadership changes effective March 1, 2026. Dr. Matt McManus will transition from his role as President, Diagnostics and Spatial Biology Segment and will remain with the company temporarily to support a smooth transition. Steve Crouse is appointed President, Diagnostics and Spatial Biology Segment.
Steve Crouse joins from Bio-Techne's Analytical Solutions Division, brings over 20 years of industry experience, and is credited with launching platforms and delivering strong growth during his four-year tenure at Bio-Techne.
Management said McManus played a key role in organizational optimization, including the strategic divestiture of the Exosome business.
Positive
- New president appointment effective March 1, 2026
- Steve Crouse brings 20+ years of life sciences leadership
- Crouse credited with launching innovative platforms and driving growth
Negative
- Leadership transition could cause short-term operational or strategic disruption
News Market Reaction
On the day this news was published, TECH declined 2.08%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
TECH was down 1.04% with below-average volume, while key peers showed a mix of small gains and losses and only 1 peer (MRNA) appeared in momentum scanners, moving down sharply without news, indicating a company-specific backdrop.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 04 | Dividend declaration | Positive | +6.3% | Quarterly cash dividend of $0.08 per share with fiscal 2025 sales detail. |
| Feb 04 | Earnings release | Positive | +6.3% | Flat revenue but higher EPS and operating margins in Q2 FY2026. |
| Feb 02 | Product launch | Positive | +1.8% | Launch of Cultrex Synthetic Hydrogel for 3D stem cell and organoid culture. |
| Jan 28 | Product launch | Positive | -3.9% | Ultra-sensitive Ella assays for neurological biomarkers with faster workflows. |
| Jan 20 | Earnings call notice | Neutral | +1.3% | Scheduling of February 4, 2026 conference call on Q2 FY2026 results. |
Recent news has often been followed by positive moves, especially around earnings and dividends, with only one notable divergence on a product launch.
Across the last few weeks, Bio‑Techne has reported stable revenue with improving profitability and margins, declared a quarterly dividend of $0.08 per share, and launched new research tools in stem cell, organoid, and neurological biomarker markets. These updates produced mostly positive price reactions, including a 6.25% move around the Q2 FY2026 results and dividend news. The current leadership transition in Diagnostics and Spatial Biology follows this sequence of operational and financial updates.
Market Pulse Summary
This announcement details a planned leadership transition in Bio‑Techne’s Diagnostics and Spatial Biology Segment, effective March 1, 2026, with an internal executive stepping into the president role. Recent filings show this segment’s margins improving alongside the Exosome divestiture, making execution under new leadership an important watchpoint. Investors may focus on how the new leader sustains growth in protein analysis instruments and immunoassays while maintaining operational efficiency.
Key Terms
immunoassays medical
AI-generated analysis. Not financial advice.
- Dr. Matt McManus to transition from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026
- Steve Crouse, Senior Vice President of Bio-Techne's Analytical Solutions Division, has been appointed President, Diagnostics and Spatial Biology Segment, effective March 1, 2026
Steve Crouse, currently Senior Vice President of Bio-Techne's Analytical Solutions Division, has been appointed President, Diagnostics and Spatial Biology Segment.
Steve has over two decades of experience as a senior life sciences leader at various companies. As Senior Vice President, Analytical Solutions Division, he is responsible for Bio-Techne's portfolio of protein analysis instruments and immunoassays and has driven strategic initiatives, successfully launched several innovative platforms and delivered strong growth during his four-year tenure. Before joining Bio-Techne, he most recently served as General Manager of Thermo Fisher Scientific's Protein Detection and Quantification business unit. He has an MBA from the Marshall School of Business at the University of
"Matt has played a key role in optimizing our organization, including driving the strategic divestiture of the Exosome business. I thank Matt for his strong leadership, positive impact on our business, and the legacy he leaves with our people, culture and innovation," said Kim Kelderman, President and Chief Executive Officer, Bio-Techne. "I'm delighted that Steve will be stepping up to take on the role of President, with his strong track record, visionary leadership, and over 20 years' experience in advancing innovative life science solutions making him an ideal fit for this role."
Kelderman added, "I'm excited for Steve to work with Will Geist, President of Bio-Techne's Protein Sciences Segment, to drive Bio-Techne's next phase of growth."
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over
Media contacts
Corporate Communications
media.relations@bio-techne.com
David Clair, Vice President, Investor Relations
david.clair@bio-techne.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-announces-changes-to-its-leadership-team-302685129.html
SOURCE Bio-Techne Corporation
FAQ
Who is replacing Dr. Matt McManus as President of Diagnostics and Spatial Biology (TECH)?
When does the Bio-Techne (TECH) leadership change take effect?
What is Steve Crouse's background before becoming President at Bio-Techne (TECH)?
Will Dr. Matt McManus remain with Bio-Techne (TECH) after March 1, 2026?
Does the Bio-Techne (TECH) announcement mention strategic transactions tied to this leadership change?
